Effect of anisodamine hydrobromide on coagulation function and prognosis of patients with sepsis-related coagulation disorders
Objective To explore the effect of anisodamine hydrobromide on the coagulation function and prognosis of patients with sepsis-related coagulation disorders and its possible mechanism.Methods A total of 72 patients with sepsis-related coagulation disorders admitted to the Department of Emergency Medicine of Affiliated Hospital of North Sichuan Medical College from April 2022 to October 2023 were prospectively selected as the research subjects,and they were divided into the control group and the treatment group by random number table method,each with 36 cases.Both groups were given conventional treatment for sepsis,and the treatment group was additionally treated with anisodamine hydrobromide.The gender,age,infection site and Sepsis-related Coagulopathy Score of all patients at enrollment were collected.The ICU stay days,total hospital stay days and 28-day mortality rate of the two groups were statistically analyzed.The Acute Physiology and Chronic Health Evaluation Ⅱ(APACHE Ⅱ)Score and coagulation function indicators[including PT,APTT,Fib,PLT and D-dimer(D-D)]of the two groups before treatment and on the 3rd,5th and 7th days of treatment were recorded.Blood samples of the two groups were collected at the same time,and the expression level of plasma syndecan-1(SDC-1)was detected by ELISA.The above indicators of the two groups were compared.Results The ICU stay days and total hospital stay days of the treatment group were both shorter than those of the control group,and the differences were statistically significant(both P＜0.05);there was no statistically significant difference in the 28-day mortality rate between the two groups(P＞0.05).The APACHE Ⅱ Score and plasma SDC-1 level of the treatment group on the 3rd,5th and 7th days of treatment were lower than those of the control group,while the PLT was higher,D-D on the 5th and 7th days of treatment were lower than those of the control group,and the differences were statistically significant(both P＜0.05);while there were no statistically significant differences in PT,APTT and Fib between the two groups on the 3rd,5th and 7th days of treatment(all P＞0.05).Conclusion Anisodamine hydrobromide can improve the coagulation function and prognosis of patients with sepsis-related coagulation disorders,and its mechanism may be related to reducing endothelial injury.
万方数据
维普
